DoseMeRx vs PrecisePK (2026)
Two Bayesian dosing platforms with genuinely different strengths. DoseMeRx is the better engineered product at the bedside, showing the pharmacist how well the model fits this patient's measured concentrations alongside the dose, which is the disclosure that tells you when to distrust the answer, and it holds HITRUST with the clearest residency statement in the segment. PrecisePK has the longest clinical lineage in this category and the best independent comparative result, and it explains its own computation step by step rather than calling it proprietary. The gap is assurance: PrecisePK publishes no attestation, no health privacy statement and no business associate terms at all. For a hospital pharmacy that is a procurement problem regardless of how good the mathematics is.
- The interface shows how well the model fits this patient's measured concentrations alongside the recommended dose, which lets a pharmacist see when the model is struggling rather than only what it concluded.
- HITRUST certification is held and the residency disclosure is the most specific in the segment, naming the cloud provider and region.
- The widest geographic footprint in the segment, which matters for a health system operating across more than one country.
- It holds the best independent comparative result in this category, which is a stronger form of evidence than any vendor run study.
- The technology page walks a reader through the actual computation in sequence, from population model through Bayesian updating, rather than describing it as proprietary.
- The longest continuous clinical lineage of any product here, developed from a pharmacokinetics service by a pharmacist, with a sixty day evaluation offered.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. DoseMeRx and PrecisePK are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | DoseMeRx | PrecisePK |
|---|---|---|
| Primary category | Medication Safety & Prescribing | Medication Safety & Prescribing |
| Founded | 2012 | Not recorded |
| Headquarters | Houston, Texas, United States | San Diego, California, United States |
| Website | doseme-rx.com | precisepk.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards DoseMeRx its top capability grade on Autonomy and Oversight Model, AI Safety and PHI Stewardship and Deployment Model and Data Residency. Set against PrecisePK, DoseMeRx grades higher on several axes, including Autonomy and Oversight Model, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Its thinnest published disclosure sits on AI Governance and Bias Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index records no top capability grade for PrecisePK on any axis it scores. Set against DoseMeRx, PrecisePK grades higher on Clinical and Operational Evidence. Its thinnest published disclosure sits on HIPAA and BAA Posture, Security Certifications and Trust Center and AI Governance and Bias Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose DoseMeRx or PrecisePK?
On the axes where the AI Health Index separates them, DoseMeRx grades higher on several axes, including Autonomy and Oversight Model, Model Supply Chain Disclosure and AI Safety and PHI Stewardship, and PrecisePK grades higher on Clinical and Operational Evidence. DoseMeRx leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do DoseMeRx and PrecisePK differ most?
The widest separation the AI Health Index records between DoseMeRx and PrecisePK is on AI Safety and PHI Stewardship, where DoseMeRx grades A and PrecisePK grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do DoseMeRx and PrecisePK grade the same?
The AI Health Index grades DoseMeRx and PrecisePK the same on several axes, including AI Centrality, Model and Technology Transparency and FDA and Regulatory Status. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have DoseMeRx and PrecisePK not disclosed?
At the last review, at least one of DoseMeRx and PrecisePK published thin or absent detail on HIPAA and BAA Posture, Security Certifications and Trust Center and AI Governance and Bias Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Neither product holds a device clearance and neither claims one, which is the settled position for therapeutic drug monitoring software, so the dose these tools compute has not been reviewed by a regulator. PrecisePK publishes no security attestation, no health privacy statement and no business associate terms across two targeted passes, which is a material gap for software handling renal function, concentrations and demographics. Neither publishes performance by age, sex, race, renal function band or body habitus, and dosing models are known to perform differently across those groups.